Literature DB >> 2562459

Crotoxin, half-century of investigations on a phospholipase A2 neurotoxin.

C Bon1, C Bouchier, V Choumet, G Faure, M S Jiang, M P Lambezat, F Radvanyi, B Saliou.   

Abstract

Crotoxin, the major toxic component of the South American rattlesnake, Crotalus durissus terrificus, is a neurotoxic phospholipase A2 which exerts its pathophysiological action by blocking the neuromuscular transmission. Crotoxin acts primarily by altering the acetylcholine release from the nerves terminals through a mechanism which has not yet been elucidated. It also acts on postsynaptic membranes by stabilizing the acetylcholine receptor in an inactive conformation very similar to the desensitized state. Crotoxin is made of two dissimilar subunits: a basic and weakly toxic phospholipase A2 component-B, and an acidic and non toxic component-A which does not possess any enzymatic activity. Binding experiments showed that crotoxin subunits dissociate when crotoxin interacts with biological membranes: Component-B binds, whereas component-A appears free in solution. The phospholipase A2 subunit binds in a non saturable, non specific manner, on any kind of biological membranes, whereas in the presence of component-A it interacts only with a limited number of high affinity binding sites present on synaptic membranes but not on erythrocyte membranes. Although the target site (acceptor) of crotoxin has not yet been formally identified, binding experiments carried out with small unilamellar phospholipid vesicles of different compositions indicate that some negatively charged phospholipids like mono and diphosphoinositide phosphates might be an important component of crotoxin acceptor site. Crotoxin is in fact a mixture of several isoforms which have very similar but not identical polypeptide sequences. An individual Crotalus durissus terrificus snake is able to synthesize several crotoxin isoforms which may result of the expression of several isogenes and/or of post-translational events. When compared in quantitative manner, the crotoxin isoforms slightly but significantly differ in their enzymatic and pharmacological properties. Finally, immunochemical investigations carried out with polyclonal antibodies prepared against both crotoxin subunits, showed that non precipitating anti-component-B- antibodies (Fab) inhibit the phospholipase A2 activity of crotoxin and neutralize its lethal potency, suggesting that the catalytic and toxic sites of crotoxin are closely related.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2562459

Source DB:  PubMed          Journal:  Acta Physiol Pharmacol Latinoam        ISSN: 0326-6656


  10 in total

1.  Biological and structural characterization of crotoxin and new isoform of crotoxin B PLA(2) (F6a) from Crotalus durissus collilineatus snake venom.

Authors:  Luis Alberto Ponce-Soto; Bruno Lomonte; Lea Rodrigues-Simioni; José Camillo Novello; Sergio Marangoni
Journal:  Protein J       Date:  2007-06       Impact factor: 2.371

2.  Snake venomics of Crotalus tigris: the minimalist toxin arsenal of the deadliest Nearctic rattlesnake venom. Evolutionary Clues for generating a pan-specific antivenom against crotalid type II venoms [corrected].

Authors:  Juan J Calvete; Alicia Pérez; Bruno Lomonte; Elda E Sánchez; Libia Sanz
Journal:  J Proteome Res       Date:  2012-01-09       Impact factor: 4.466

3.  Biochemical, pharmacological and structural characterization of a new PLA2 from Crotalus durissus terrificus (South American rattlesnake) venom.

Authors:  Saraguaci Hernandez-Oliveira; Marcos Hikari Toyama; Daniela Oliveira Toyama; Sergio Marangoni; Stephen Hyslop; Léa Rodrigues-Simioni
Journal:  Protein J       Date:  2005-05       Impact factor: 2.371

4.  Crystallization and preliminary X-ray crystallographic analysis of the heterodimeric crotoxin complex and the isolated subunits crotapotin and phospholipase A2.

Authors:  K F Santos; M T Murakami; A C O Cintra; M H Toyama; S Marangoni; V P Forrer; J R Brandão Neto; I Polikarpov; R K Arni
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-03-12

5.  Biochemical, pharmacological and structural characterization of two PLA2 isoforms Cdr-12 and Cdr-13 from Crotalus durissus ruruima snake venom.

Authors:  Luis Alberto Ponce-Soto; Paulo Aparecido Baldasso; Frey Francisco Romero-Vargas; Flávia V Winck; José Camillo Novello; Sergio Marangoni
Journal:  Protein J       Date:  2007-01       Impact factor: 4.000

6.  Role of crotoxin, a phospholipase A2 isolated from Crotalus durissus terrificus snake venom, on inflammatory and immune reactions.

Authors:  D F Cardoso; M Lopes-Ferreira; E L Faquim-Mauro; M S Macedo; S H Farsky
Journal:  Mediators Inflamm       Date:  2001-06       Impact factor: 4.711

7.  Antivenomics as a tool to improve the neutralizing capacity of the crotalic antivenom: a study with crotamine.

Authors:  Ricardo Teixeira-Araújo; Patrícia Castanheira; Leonora Brazil-Más; Francisco Pontes; Moema Leitão de Araújo; Maria Lucia Machado Alves; Russolina Benedeta Zingali; Carlos Correa-Netto
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2017-05-12

8.  Innovative design for a phase 1 trial with intra-patient dose escalation: The Crotoxin study.

Authors:  Jacques Medioni; Mara Brizard; Reza Elaidi; Paul F Reid; Khadija Benlhassan; Dorothy Bray
Journal:  Contemp Clin Trials Commun       Date:  2017-07-23

9.  Pharmacological characterization of crotamine effects on mice hind limb paralysis employing both ex vivo and in vivo assays: Insights into the involvement of voltage-gated ion channels in the crotamine action on skeletal muscles.

Authors:  Sunamita de Carvalho Lima; Lucas de Carvalho Porta; Álvaro da Costa Lima; Joana D'Arc Campeiro; Ywlliane Meurer; Nathália Bernardes Teixeira; Thiago Duarte; Eduardo Brandt Oliveira; Gisele Picolo; Rosely Oliveira Godinho; Regina Helena Silva; Mirian Akemi Furuie Hayashi
Journal:  PLoS Negl Trop Dis       Date:  2018-08-06

10.  Crotalus durissus ruruima Snake Venom and a Phospholipase A2 Isolated from This Venom Elicit Macrophages to Form Lipid Droplets and Synthesize Inflammatory Lipid Mediators.

Authors:  Ana Eduarda Zulim de Carvalho; Karina Giannotti; Elbio Leiguez Junior; Márcio Matsubara; Maria Cristina Dos Santos; Consuelo Latorre Fortes-Dias; Catarina Teixeira
Journal:  J Immunol Res       Date:  2019-11-04       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.